Neuropatía óptica autoinmune recidivante bilateral en la infancia

Clinical case: A ten year-old girl, after a Yersinia gastroenteritis, developed an optic neuritis in the left eye. She was not treated and resulted ultimately in optic atrophy on the affected side. Six months later a similar episode occurred in the contralateral eye. On this occasion corticosteroid...

ver descrição completa

Detalhes bibliográficos
Autores: Garcia-Gomez, P.J. (Pío J.)|||/items/0e1f3ab5-b2a4-4c4a-9017-b8934d93f641, Belzunce, A. (Arnaldo)|||/items/4d59e1b4-b5e4-4a04-870d-a2371e54adc4, Salinas-Alaman, A. (Ángel)|||/items/ac6c3088-aae2-4d82-97b0-d087742c1901, Heras-Mulero, H. (Henar)|||/items/7b527397-8e3a-4d0a-9433-3da0d383a878, Sadaba-Echarri, L.M. (Luis Manuel)|||/items/f4df381d-5180-416f-b01c-67598e7d4149
Formato: artículo
Fecha de publicación:2006
País:España
Recursos:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:español
OAI Identifier:oai:dadun.unav.edu:10171/23526
Acesso em linha:https://hdl.handle.net/10171/23526
Access Level:acceso abierto
Palavra-chave:Autoimmune optic neuritis
bilateral optic neuritis
Azathioprine
Descrição
Resumo:Clinical case: A ten year-old girl, after a Yersinia gastroenteritis, developed an optic neuritis in the left eye. She was not treated and resulted ultimately in optic atrophy on the affected side. Six months later a similar episode occurred in the contralateral eye. On this occasion corticosteroid therapy was given. During this therapy the neuritis diminished; however the patient had three relapses, so it was decided to give her immunosuppressive treatment with azathioprine and continue this indefinitely. Discussion: After considering the differential diagnoses of bilateral recurrent optical neuritis in childhood, we concluded that it was most likely to have an autoimmune basis. After considering the benefits and risks of the long-term treatment, we believe immunosuppressive therapy is most useful in controlling the disease allowing corticosteroid therapy to be reduced (Arch Soc Esp Oftalmol 2006; 81: 607-610).